Concepts (136)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stomach Neoplasms | 29 | 2024 | 113 | 14.220 |
Why?
|
| Immunotherapy | 9 | 2024 | 94 | 2.640 |
Why?
|
| Tomography, X-Ray Computed | 13 | 2024 | 950 | 2.490 |
Why?
|
| Chemotherapy, Adjuvant | 11 | 2024 | 205 | 2.140 |
Why?
|
| Peritoneal Neoplasms | 3 | 2023 | 263 | 1.750 |
Why?
|
| Prognosis | 18 | 2024 | 1547 | 1.750 |
Why?
|
| Artificial Intelligence | 4 | 2023 | 64 | 1.310 |
Why?
|
| Retrospective Studies | 13 | 2024 | 3708 | 1.100 |
Why?
|
| Humans | 39 | 2025 | 32952 | 1.020 |
Why?
|
| Algorithms | 6 | 2024 | 517 | 0.930 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 599 | 0.870 |
Why?
|
| Neoplasm Staging | 7 | 2023 | 471 | 0.870 |
Why?
|
| Middle Aged | 17 | 2024 | 12202 | 0.860 |
Why?
|
| Gastrectomy | 2 | 2023 | 70 | 0.830 |
Why?
|
| Predictive Value of Tests | 6 | 2022 | 894 | 0.810 |
Why?
|
| Aged | 12 | 2024 | 10624 | 0.740 |
Why?
|
| Female | 20 | 2024 | 20363 | 0.740 |
Why?
|
| Male | 19 | 2024 | 19743 | 0.730 |
Why?
|
| Medical Oncology | 1 | 2023 | 92 | 0.720 |
Why?
|
| p21-Activated Kinases | 2 | 2022 | 5 | 0.720 |
Why?
|
| Stomach | 1 | 2021 | 17 | 0.690 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2022 | 107 | 0.680 |
Why?
|
| Disease-Free Survival | 5 | 2022 | 326 | 0.670 |
Why?
|
| China | 4 | 2021 | 54 | 0.640 |
Why?
|
| Drug Monitoring | 1 | 2018 | 28 | 0.570 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2018 | 51 | 0.570 |
Why?
|
| Survival Analysis | 5 | 2018 | 486 | 0.540 |
Why?
|
| Brain Neoplasms | 1 | 2023 | 647 | 0.540 |
Why?
|
| Neoplasms | 4 | 2025 | 762 | 0.520 |
Why?
|
| Up-Regulation | 1 | 2017 | 191 | 0.500 |
Why?
|
| ROC Curve | 4 | 2023 | 169 | 0.490 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 134 | 0.480 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 384 | 0.470 |
Why?
|
| Image Processing, Computer-Assisted | 7 | 2024 | 225 | 0.410 |
Why?
|
| Nomograms | 3 | 2021 | 35 | 0.350 |
Why?
|
| Cone-Beam Computed Tomography | 3 | 2024 | 20 | 0.320 |
Why?
|
| Fluorouracil | 2 | 2022 | 82 | 0.310 |
Why?
|
| Treatment Outcome | 4 | 2020 | 3460 | 0.280 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2025 | 91 | 0.270 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 765 | 0.260 |
Why?
|
| Adult | 5 | 2020 | 9586 | 0.260 |
Why?
|
| Immunohistochemistry | 2 | 2018 | 497 | 0.250 |
Why?
|
| Adenocarcinoma | 2 | 2020 | 300 | 0.240 |
Why?
|
| Age Factors | 2 | 2020 | 1202 | 0.230 |
Why?
|
| Computational Biology | 1 | 2025 | 96 | 0.230 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 457 | 0.220 |
Why?
|
| Young Adult | 3 | 2020 | 2738 | 0.210 |
Why?
|
| Radiography | 2 | 2023 | 386 | 0.210 |
Why?
|
| Biology | 1 | 2023 | 2 | 0.200 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 4057 | 0.200 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2024 | 42 | 0.200 |
Why?
|
| Gene Expression Profiling | 1 | 2024 | 319 | 0.200 |
Why?
|
| Radiology | 1 | 2023 | 45 | 0.190 |
Why?
|
| Artifacts | 1 | 2023 | 42 | 0.190 |
Why?
|
| Cell Line, Tumor | 2 | 2022 | 727 | 0.190 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2024 | 158 | 0.190 |
Why?
|
| Forecasting | 1 | 2023 | 143 | 0.190 |
Why?
|
| Lymphatic Metastasis | 2 | 2021 | 169 | 0.170 |
Why?
|
| Area Under Curve | 1 | 2021 | 92 | 0.170 |
Why?
|
| SEER Program | 1 | 2020 | 33 | 0.170 |
Why?
|
| Reproducibility of Results | 2 | 2023 | 770 | 0.160 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 24 | 0.160 |
Why?
|
| Neoplasm Invasiveness | 2 | 2017 | 193 | 0.160 |
Why?
|
| Fibroblasts | 1 | 2020 | 115 | 0.150 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 576 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2017 | 265 | 0.150 |
Why?
|
| Endothelial Cells | 1 | 2020 | 197 | 0.140 |
Why?
|
| Tumor Burden | 1 | 2018 | 61 | 0.140 |
Why?
|
| Serum Response Factor | 1 | 2017 | 1 | 0.130 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2017 | 8 | 0.130 |
Why?
|
| CA-19-9 Antigen | 1 | 2017 | 7 | 0.130 |
Why?
|
| Propionates | 1 | 2017 | 5 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2017 | 11 | 0.130 |
Why?
|
| Growth and Development | 1 | 2017 | 3 | 0.130 |
Why?
|
| Endonucleases | 1 | 2017 | 4 | 0.130 |
Why?
|
| Organogenesis | 1 | 2017 | 18 | 0.130 |
Why?
|
| Thymidylate Synthase | 1 | 2017 | 15 | 0.130 |
Why?
|
| Gastrointestinal Tract | 1 | 2017 | 31 | 0.130 |
Why?
|
| Ki-67 Antigen | 1 | 2017 | 29 | 0.130 |
Why?
|
| Organoplatinum Compounds | 1 | 2017 | 46 | 0.130 |
Why?
|
| Cyclooxygenase 2 | 1 | 2017 | 50 | 0.130 |
Why?
|
| Molecular Motor Proteins | 1 | 2017 | 58 | 0.130 |
Why?
|
| Myosin Heavy Chains | 1 | 2017 | 89 | 0.130 |
Why?
|
| Comorbidity | 1 | 2018 | 573 | 0.130 |
Why?
|
| DNA-Binding Proteins | 1 | 2017 | 142 | 0.130 |
Why?
|
| Breast Neoplasms | 1 | 2023 | 754 | 0.120 |
Why?
|
| Interleukin-17 | 1 | 2016 | 26 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 1 | 2016 | 80 | 0.120 |
Why?
|
| Dietary Supplements | 1 | 2017 | 187 | 0.120 |
Why?
|
| MicroRNAs | 1 | 2017 | 190 | 0.110 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2014 | 5 | 0.110 |
Why?
|
| Prospective Studies | 1 | 2020 | 2338 | 0.110 |
Why?
|
| Thyroidectomy | 1 | 2014 | 20 | 0.110 |
Why?
|
| Dexamethasone | 1 | 2014 | 47 | 0.110 |
Why?
|
| Signal Transduction | 1 | 2017 | 689 | 0.100 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2023 | 30 | 0.100 |
Why?
|
| Inflammation | 1 | 2016 | 542 | 0.100 |
Why?
|
| Adolescent | 1 | 2020 | 3643 | 0.090 |
Why?
|
| United States | 1 | 2020 | 4132 | 0.090 |
Why?
|
| Neutrophils | 2 | 2022 | 110 | 0.080 |
Why?
|
| Disease Progression | 2 | 2024 | 594 | 0.070 |
Why?
|
| Tissue Array Analysis | 1 | 2025 | 36 | 0.060 |
Why?
|
| Staining and Labeling | 1 | 2024 | 58 | 0.050 |
Why?
|
| Hematoxylin | 1 | 2024 | 4 | 0.050 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2024 | 5 | 0.050 |
Why?
|
| X-Rays | 1 | 2023 | 6 | 0.050 |
Why?
|
| Histological Techniques | 1 | 2023 | 8 | 0.050 |
Why?
|
| Neck | 1 | 2023 | 31 | 0.050 |
Why?
|
| Metals | 1 | 2023 | 17 | 0.050 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2023 | 10 | 0.050 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2023 | 134 | 0.050 |
Why?
|
| Phantoms, Imaging | 1 | 2023 | 59 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2022 | 59 | 0.050 |
Why?
|
| Phenotype | 1 | 2023 | 644 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2021 | 114 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 1 | 2020 | 46 | 0.040 |
Why?
|
| Anilides | 1 | 2017 | 11 | 0.030 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2017 | 11 | 0.030 |
Why?
|
| Animal Feed | 1 | 2017 | 17 | 0.030 |
Why?
|
| Cattle | 1 | 2017 | 108 | 0.030 |
Why?
|
| Benzamides | 1 | 2017 | 54 | 0.030 |
Why?
|
| Base Sequence | 1 | 2017 | 249 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2017 | 134 | 0.030 |
Why?
|
| Cell Movement | 1 | 2017 | 173 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 2016 | 58 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2016 | 71 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 220 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2016 | 118 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2020 | 1852 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2017 | 500 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 682 | 0.030 |
Why?
|
| Body Weight | 1 | 2017 | 302 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2017 | 604 | 0.030 |
Why?
|
| Diet | 1 | 2017 | 393 | 0.030 |
Why?
|
| Risk Factors | 1 | 2020 | 4001 | 0.020 |
Why?
|
| Animals | 1 | 2017 | 7598 | 0.010 |
Why?
|